Chembio announces the receipt of clia waiver for its dpp hiv-syphilis system

Medford, n.y., feb. 24, 2023 (globe newswire) -- chembio diagnostics, inc. (nasdaq: cemi), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a clinical laboratory improvement amendments (clia) waiver from the u.s. food and drug administration (fda) for the dpp hiv-syphilis system.

CEMI Ratings Summary

CEMI Quant Ranking